Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension
Inhibition of the angiotensin I-converting enzyme (ACE) is a widely used principle for the treatment of hypertension. Fermentation of milk proteins was shown to lead to the formation of peptides with ACE-inhibiting activity. Milk products with ACE-inhibiting peptides may provide a useful approach to prevent or treat hypertension.
Aim of the study
To investigate the effect of a milk drink supplemented with whey peptides on blood pressure in mildly hypertensive subjects.
A randomized, placebo-controlled, double blind clinical trial in two parallel groups was performed. A total of 54 hypertensive patients received either 125 ml of a milk drink supplemented with whey peptides every morning or a control product for 12 weeks after a run-in period of 2 weeks. Previous in vitro tests of the whey powder demonstrated ACE-inhibitory activity. Blood pressure was measured at 0, 2, 4, 8, and 12 weeks. Fasting blood samples were collected at 0, 4, 8, and 12 weeks for analysis of metabolic and inflammatory variables.
Resting systolic and diastolic blood pressure values did not change in the milk drink group 144.1 ± 8.6/91.0 ± 5.5 mmHg at baseline vs. 143.7 ± 13.5/90.4 ± 6.5 mmHg after 12 weeks. In the control group systolic (p = 0.0431) and diastolic (p = 0.0081) blood pressure was significantly reduced 140.6 ± 11.7/90.3 ± 5.8 mmHg at baseline vs. 137.0 ± 14.4/87.7 ± 6.6 mmHg after 12 weeks. There was no difference between the two groups at any time point. No changes were seen when the results of the 24-h continuous blood pressure monitoring were compared after 12 weeks. No significant changes were detected for circulating levels of selected inflammation markers (interleukin (IL)-6, C-reactive protein (CRP), number of leukocytes, and plasminogen activator inhibitor-1 (PAI-1) as well as for metabolic variables (insulin, plasma glucose, and lipids).
The daily consumption of 125 ml of a milk drink supplemented with whey peptides was not found to reduce blood pressure and/or inflammation markers in mildly hypertensive subjects, although preceding in vitro tests showed a potent ACE-inhibition.
Keywordsangiotensin I-converting enzyme whey bioactive peptides hypertension
- 2.Goldstein LB, Adams R, Becker K, et al. (2001) Primary prevention of ischemic stroke. American Heart Association. Circulation 103:163–182Google Scholar
- 3.Abbott RD, Curb JD, Rodriguez BL, et al. (1996) Effect of dietary calcium and milk consumption on the risk of thrombolic stroke in older middle-aged men. The Honolulu Heart Program. Stroke 27:813–818Google Scholar
- 5.Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T (1996) A study on the effect of sour milk on blood pressure in hypertensive patients. Am J Clin Nutr 64:767–771Google Scholar
- 6.Seppo L, Jauhiainen T, Poussa T, Korpela R (2003) A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77:326–330Google Scholar
- 7.Korhonen H, Pihlanto-Leppala A, Rantamaki P, Tupasela T (1998) The functional and biological properties of whey proteins: prospects for the development of functional foods. Agric Food Sci Finland 7:283–296Google Scholar
- 10.Meisel H, Schlimme E (1994) Inhibitors of angiotensin-I-converting enzyme derived from bovine casein (casokinins). In: Branil V, Teschemacher H (eds) β-Casomorphins and related peptides: recent development, Weinheim, VCH, GermanyGoogle Scholar
- 11.Maruyama S, Nakagomi K, Tomizuka N, Suzuki H (1985) Angiotensin-I-converting enzyme inhibitor derived and enzymatic hydrolysate of casein II. Isolation and bradykinin-potentiating activity on uterus and the ileum of rats. Agric Biol Chem 49:1405–1409Google Scholar
- 12.Maruyama S, Mitachi H, Tanaka H, Tomizuka N, Suzuki H (1987a) Studies on the active site and antihypertensive activity of angiotensin I-converting enzyme inhibitors derived from casein. Agric Biol Chem 51:1581–1586Google Scholar
- 13.Maruyama S, Mitachi H, Tanaka H, Tomizuka N, Suzuki H (1987b) Angiotensin-I-converting enzyme inhibitory activity of the C-terminal hexapeptide of αs1-casein. Agric Biol Chem 51:2557–2561Google Scholar
- 14.Kohmura M, Nio N, Kubo K, Minoshima Y, Munekata E, Ariyoshi Y (1989) Inhibition of angiotensin-converting enzyme by synthetic peptides of human β-casein. Agric Biol Chem 53:2107–2114Google Scholar